UK markets open in 6 hours 47 minutes

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
362.00-3.00 (-0.82%)
At close: 03:44PM BST

MaxCyte, Inc.

9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700
https://www.maxcyte.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees143

Key executives

NameTitlePayExercisedYear born
Mr. Maher MasoudPresident, CEO & Director509.75kN/A1976
Mr. Douglas Arthur DoerflerFounder1.83MN/A1956
Mr. Douglas J. Swirsky CFA, CPAChief Financial Officer475.63kN/A1969
Mr. Jay GelfmanSenior Vice President of OperationsN/AN/AN/A
Mr. Ronald Evan Holtz CPA, Ph.D.Executive Vice President of Administration508.5kN/A1958
Mr. David SandovalSenior Vice President, General Counsel & Corporate SecretaryN/AN/AN/A
Mr. Thomas Michael RossExecutive Vice President of Global SalesN/AN/A1961
Mr. Jack HorganVice President of Corporate DevelopmentN/AN/AN/A
Ms. Jill MayerSenior Vice President of Human ResourcesN/AN/AN/A
Dr. J. Stark Thompson Ph.D.Consultant66.33kN/A1942
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Corporate governance

MaxCyte, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.